In Phoenix, at the American College of Allergy, Asthma and Immunology's gathering in mid-November 2026, a Dallas physician-researcher offered a quiet observation about a rare inherited condition that strikes without warning. Children with hereditary angioedema live under the threat of sudden swelling, and the families who watch over them have long carried that uncertainty alongside their own lives. A small retrospective look at thirteen young patients on the preventive drug lanadelumab suggests that, for many of these households, the weight has eased considerably, though the sample is too mode
Lanadelumab Linked to Better Quality of Life for Children With HAE and Their Caregivers
Before treatment, caregivers reported widespread disruption to sleep, work, recreation, and family life caused by their child's unpredictable HAE attacks.
Caregiver quality of life rose from 1.9 to 4.5 on a 5-point scale
Mark
Why do these numbers matter beyond the drug's attack-prevention results?
Mimi
Because the burden of HAE falls on the household. Before treatment, 85% of caregivers reported impaired sleep and 68% had to ask for work flexibility or make other adjustments.
Mark
And afterward?
Mimi
Impaired sleep fell to 31%, and 69% reported no work or daily activity impact.
Luke
Keep the sample in view, though. That's 11 caregivers reporting on 13 children.
Mark
So how far can the findings travel?
Luke
Not far yet. It's retrospective, so the before ratings are recalled, not measured at the time. Everything is caregiver-reported, and there's no comparison group.
Mimi
Still, the shift is large, from 1.9 to 4.5 for caregivers' own quality of life.
Mark
Was anything unchanged?
Mimi
Communication and worry about unpredictable attacks didn't change significantly. The fear seems to outlast the disruption.
Luke
I'd be careful with that reading. The source only says those two domains didn't change significantly; it doesn't say why, and with this few people, that could mean many things.
O Pulso
- Caregivers once rated their own quality of life at 1.9 out of 5, a figure that reveals how deeply unpredictable attacks had reached into every corner of family life.
- Before treatment, most caregivers were scrambling for schedule changes, missed work, and lost sleep, with 85 percent reporting disrupted nights.
- After lanadelumab, the share reporting no work impact climbed from 23 to 69 percent, and impaired sleep fell to 31 percent.
- The findings rest on eleven caregivers and thirteen children, all retrospective and caregiver-reported, so the trajectory remains promising but unconfirmed.
- Worry about the next attack and communication within families did not shift meaningfully, leaving a lingering tension that larger prospective studies must still address.
In Phoenix, at the American College of Allergy, Asthma and Immunology's gathering in mid-November 2026, a Dallas physician-researcher offered a quiet observation about a rare inherited condition that strikes without warning. Children with hereditary angioedema live under the threat of sudden swelling, and the families who watch over them have long carried that uncertainty alongside their own lives. A small retrospective look at thirteen young patients on the preventive drug lanadelumab suggests that, for many of these households, the weight has eased considerably, though the sample is too modest to settle the question for everyone.
At the American College of Allergy, Asthma and Immunology annual meeting in Phoenix, William R. Lumry, MD, a clinical professor at UT Southwestern in Dallas, presented a late-breaking look at children with hereditary angioedema and the adults who care for them. The question was what happens after years on lanadelumab, the preventive drug the FDA extended to children aged 2 to under 12 in 2023. The headline was striking: caregivers rated their own quality of life at 1.9 out of 5 before treatment and 4.5 during it.
Before lanadelumab, the disease had shaped whole households. Attacks came without warning, and most caregivers had been forced to ask for flexibility, stop working, or rearrange their days. Sleep was broken for most of them, and recreation and family time had been pushed aside. Once children were on prophylaxis, those burdens loosened. Caregivers reporting no work impact rose from 23 percent to 69 percent, and impaired sleep fell from 85 percent to 31 percent.
The sample is small: eleven caregivers reporting on thirteen patients, with all data gathered retrospectively and from the caregivers' own perspective. Worry about attacks and communication within families did not change significantly. Lumry was clear that larger prospective studies will be needed to confirm what these families appear to have gained.
At the American College of Allergy, Asthma and Immunology annual meeting in Phoenix, William R. Lumry, MD, presented a late-breaking analysis of what happens to children with hereditary angioedema, and to the adults caring for them, after years on the preventive drug lanadelumab (Takhzyro). The meeting ran November 12 to 16, 2026. The headline figure: caregivers rated their own quality of life at 1.9 on a 5-point scale before treatment and 4.5 during it.
Lumry is a clinical professor of internal medicine at the University of Texas Southwestern Medical School in Dallas. He described the shift to HCPLive in blunt terms: a complete flip in how patients and caregivers perceived quality of life with treatment. The work is a retrospective registry analysis, and it looks at routine practice rather than a controlled trial.
Some background on the drug. In February 2023, the US Food and Drug Administration expanded the lanadelumab label to include children aged 2 to under 12 years. That decision rested on the open-label phase 3 SPRING study, plus efficacy data extrapolated from the phase 3 HELP study. SPRING had already reported large gains in caregiver-reported Pediatric Quality of Life Inventory (PedsQL) scores over 52 weeks. The new analysis asks a longer-term question about both quality of life and the burden of caregiving.
The sample is small. Eleven caregivers, with a mean age of 42.3 years and 64% of them female, reported on 13 pediatric patients. The patients had a mean age of 12.2 years, and 62% were male. They began lanadelumab at a mean age of 8.9 years and had been treated for a mean of 3.7 years.
On the 5-point scale, where 1 is poor and 5 is excellent, caregivers rated patient quality of life at a mean of 2.2 before lanadelumab and 4.7 in the current period. During treatment, mean PedsQL total scores were 68.5 for patients aged 5 to 7, 91 for those aged 8 to 12, and 84 for those aged 13 to 18.
The effects on caregivers' working and daily lives were stark. During treatment, 69% of caregivers said their child's HAE had no impact on work or daily activities. Before lanadelumab, only 23% reported no work impact and just 8% reported no daily activity impact. Lumry noted that 68% of caregivers had needed to ask for flexibility, stop working, or make other adjustments before their child began prophylaxis.
Other measures moved the same way. On the PedsQL Family Impact Module, scores during treatment were 92 (SD 13) for family functioning and 90 (SD 20) for daily activities. The share of caregivers reporting impaired sleep fell from 85% before treatment to 31% during it. Impact on recreational activities dropped from 62% to 8%, and work responsibilities showed the identical shift. Errands, household chores, and family time had affected 30% to 45% of caregivers before treatment; none reported an impact during it.
Two domains did not budge significantly: communication, and worry about unpredictable attacks. Lumry called the study a multidimensional assessment of the broader impact of a very effective treatment in children and in their caregivers. The limits are plain, though. The data are retrospective and caregiver-reported, and they come from 13 patients, so larger prospective studies would be needed to confirm the gains. Lumry's disclosures include Novartis, CSL Behring, Takeda, and BioCryst, among others.
Citações Notáveis
It was just a complete flip in what the patients and the caregivers perceived as far as their quality of life with treatment.— William R. Lumry, MD, University of Texas Southwestern Medical School
Quer a matéria completa?
Leia o original em HCPLive ↗